12th Neuro-Oncology Brain Tumor Symposium

---

LIVECMECNE

Friday, January 31, 2025, 7:30 AM - 4:00 PM, Law Auditorium, Philadelphia, PA

The purpose of this educational activity is to provide a review of new treatment options in neuro-oncology, including surgical techniques, and intraoperative imaging, along with, radiation and systemic therapies that have improved patient outcomes. Sessions will feature the latest advances in state-of-the-art care for practicing clinicians treating patients with brain tumors. Cutting-edge topics in precision medicine, including genetic, translational, and clinical research will also be featured. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care. Participants will leave with up-to-date, practical information which will have immediate clinical application, as well as technical and scientific background on the current state, and where the latest scientific advances may take the field.

1. Evaluate the latest advancements in brain cancer diagnosis and treatment.
2. Review the role of innovative technologies like LITT, molecular profiling, and neuroimaging in improving patient care.
3. Analyze the current landscape of CAR T-cell therapy for brain tumors and its future potential.
4. Describe emerging technologies and strategies for optimizing surgery and immunotherapy for gliomas.
5. Assess the impact of the INDIGO trial on the treatment of IDH-mutant low-grade gliomas.
6. Review practical knowledge in medical and symptom management for patients with brain tumors.
7. Evaluate the latest advancements in liquid biopsy, radiation therapy, and targeted treatments for brain tumors.
8. Discuss the potential of mRNA technology and intraoperative molecular imaging in improving outcomes for brain tumor patients.

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit
Physicians: Penn Medicine designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 7.50 Category 1 credits for completing this activity.

Nurses: This program provides 7.50 NCPD Hours.

ABS MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn 7.50 credits toward the CME and Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

AMA PRA Category 1 Credits™ (7.50 hours), NCPD Hours (ANCC) (7.50 hours), Non-Physician Attendance / Participation (7.50 hours)

Mitigation of Relevant Financial Relationships

Penn Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Friday, January 31, 2025